MAMMALIAN METABOLISM OF 4-HYDROXYBUTYRIC ACID
4-羟基丁酸的哺乳动物代谢
基本信息
- 批准号:3450073
- 负责人:
- 金额:$ 5.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1986
- 资助国家:美国
- 起止时间:1986-08-01 至 1989-07-31
- 项目状态:已结题
- 来源:
- 关键词:Krebs' cycle brain metabolism chromatography electrophoresis enzyme complex fatty acid metabolism gamma hydroxybutyrate gas chromatography mass spectrometry high performance liquid chromatography inborn metabolism disorder ion exchange chromatography liver metabolism molecular pathology neurochemistry oxidation radioassay
项目摘要
4-Hydroxybutyric acid, an analog of the well known inhibitory
neurotransmitter GABA, is a compound known to display both
neuropharmacologic and neurophysiologic properties. A recently expanding
body of evidence suggests that 4-hydroxybutyric acid, much like L-glutamate
and GABA, functions in mammalian brain as a neurotransmitter. Furthermore,
4-hydroxybutyric acid is known to accumulate in the brain of patients with
Huntington's chorea, Parkinson's disease and is excreted in large
quantities in the urine of patients with a recently described inborn error
of metabolism, 4-hydroxybutyric aciduria. In this latter pathological
state, due to a deficiency of the GABA degradative enzyme succinic
semialdehyde dehydrogenase, the six known patients have displayed a severe
clinical picture of neurological deterioration, presumably due to the
accumulation of 4-hydroxybutyric acid. Although known to exert
neuropharmacologic activity, there is very little evidence concerning the
mechanism by which 4-hydroxybutyric acid is metabolized. Initial studies
suggest a mechanism of Beta-oxidation in peripheral organs and oxidation to
the level of citric acid cycle intermediates in the brain. It is proposed
to carry out a systematic investigation of the metabolism of
4-hydroxybutyric acid in the liver and brain of the rat. Radiolabeled and
deuterated materials will be employed with quantification and metabolite
identification by reverse phase HPLC and GCMS. In vivo characterization of
4-hydroxybutyric acid metabolism will be afforded by monitoring whole body
metabolism in the intact rat. The probable role of 4-hydroxybutyric acid
as neurotransmitter in mammalian brain warrants a systematic study of this
molecule's degradative pathway. This fact alone should justify the
proposed basic research investigation. However, clinical implications may
also be involved. It remains possible that a thorough knowledge of the
degradative pathway will afford a mechanism for stimulation. Evidence in
this direction could be of therapeutic value to patients with severe
pathologies such as Huntington's chorea, Parkinson's disease and
4-hydroxybutyric aciduria.
4-羟基丁酸,一种众所周知的抑制剂的类似物,
神经递质GABA是一种已知的化合物,
神经药理学和神经生理学特性。 一个最近不断扩大的
大量证据表明,4-羟基丁酸,很像L-谷氨酸
和GABA,在哺乳动物大脑中作为神经递质发挥作用。 此外,委员会认为,
4-已知羟丁酸在患有以下疾病的患者的大脑中积累:
亨廷顿舞蹈病、帕金森氏病和大排特
最近描述的先天性缺陷患者尿液中的含量
4-羟丁酸尿症 在后一种病理学中,
状态,由于缺乏GABA降解酶琥珀酸
半醛脱氢酶,六个已知的患者表现出严重的
神经功能恶化的临床表现,可能是由于
4-羟基丁酸的积累。 虽然众所周知,
神经药理学活性,很少有证据表明,
4-羟基丁酸的代谢机制。 初步研究
提示外周器官中β-氧化和氧化至
大脑中柠檬酸循环中间产物的水平。 拟
进行系统的代谢研究,
4-羟丁酸在大鼠的肝脏和大脑中。 放射性标记和
氘代材料将用于定量和代谢物
通过反相HPLC和GCMS鉴定。 的体内表征
4-羟丁酸代谢将通过监测全身来提供
在完整大鼠中的代谢。 4-羟丁酸的可能作用
作为哺乳动物大脑中的神经递质,
分子的降解途径。 仅这一事实就足以证明
提出基础研究调查。 然而,临床意义可能
也参与其中。 但仍然有可能,
降解途径将提供刺激机制。 证据
这一方向可能对严重的
例如亨廷顿舞蹈病、帕金森病和
4-羟丁酸尿症
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
K Michael GIBSON其他文献
K Michael GIBSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('K Michael GIBSON', 18)}}的其他基金
Natural History of Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD), a Heritable Disorder of GABA Metabolism
琥珀半醛脱氢酶缺乏症 (SSADHD) 的自然史,一种 GABA 代谢的遗传性疾病
- 批准号:
10200868 - 财政年份:2018
- 资助金额:
$ 5.36万 - 项目类别:
Rapalog Therapy in Heritable and Vigabatrin-Induced GABA Metabolic Disorders
Rapalog 疗法治疗遗传性和氨己烯酸诱导的 GABA 代谢紊乱
- 批准号:
9555110 - 财政年份:2017
- 资助金额:
$ 5.36万 - 项目类别:
Rapalog Therapy in Heritable and Vigabatrin-Induced GABA Metabolic Disorders
Rapalog 疗法治疗遗传性和氨己烯酸诱导的 GABA 代谢紊乱
- 批准号:
9918905 - 财政年份:2017
- 资助金额:
$ 5.36万 - 项目类别:
Therapeutics of mTOR Signaling in Succinic Semialdehyde Dehydrogenase Deficiency
mTOR 信号转导治疗琥珀酸半醛脱氢酶缺乏症
- 批准号:
8769623 - 财政年份:2014
- 资助金额:
$ 5.36万 - 项目类别:
Therapeutics of mTOR Signaling in Succinic Semialdehyde Dehydrogenase Deficiency
mTOR 信号转导治疗琥珀酸半醛脱氢酶缺乏症
- 批准号:
8848901 - 财政年份:2014
- 资助金额:
$ 5.36万 - 项目类别:
Phase II Trial of SGS-742 in Succinic Semialdehyde Dehydrogenase Deficiency
SGS-742 治疗琥珀酸半醛脱氢酶缺乏症的 II 期试验
- 批准号:
9026653 - 财政年份:2013
- 资助金额:
$ 5.36万 - 项目类别:
Phase II Trial of SGS-742 in Succinic Semialdehyde Dehydrogenase Deficiency
SGS-742 治疗琥珀酸半醛脱氢酶缺乏症的 II 期试验
- 批准号:
8479999 - 财政年份:2013
- 资助金额:
$ 5.36万 - 项目类别:
Phase II Trial of SGS-742 in Succinic Semialdehyde Dehydrogenase Deficiency
SGS-742 治疗琥珀酸半醛脱氢酶缺乏症的 II 期试验
- 批准号:
8617315 - 财政年份:2013
- 资助金额:
$ 5.36万 - 项目类别:
Novel Treatment & Screening Strategies in Gamma-Hydroxybutyric Aciduria
新颖的治疗方法
- 批准号:
8390456 - 财政年份:2008
- 资助金额:
$ 5.36万 - 项目类别:
相似海外基金
Brain metabolism across the lifespan using multi-parametric MRS
使用多参数 MRS 分析整个生命周期的脑代谢
- 批准号:
10738647 - 财政年份:2023
- 资助金额:
$ 5.36万 - 项目类别:
Quantifying the Brain Metabolism Underlying Task-Based BOLD Imaging
量化基于任务的 BOLD 成像背后的大脑代谢
- 批准号:
10432379 - 财政年份:2022
- 资助金额:
$ 5.36万 - 项目类别:
Novel 10.5 T deuterium-based MRS/I method to measure brain metabolism
测量脑代谢的新型 10.5 T 氘 MRS/I 方法
- 批准号:
10442075 - 财政年份:2022
- 资助金额:
$ 5.36万 - 项目类别:
Neuroimaging study of the effects of phospholipase A2 (PLA2) inhibition on brain metabolism and neuroinflammation in a rat model of Alzheimer’s Disease.
神经影像学研究磷脂酶 A2 (PLA2) 抑制对阿尔茨海默病大鼠模型脑代谢和神经炎症的影响。
- 批准号:
486273 - 财政年份:2022
- 资助金额:
$ 5.36万 - 项目类别:
Studentship Programs
Dynamics of Cellular Brain Metabolism Using Mass Spectrometry Imaging
使用质谱成像研究细胞脑代谢动力学
- 批准号:
10556434 - 财政年份:2022
- 资助金额:
$ 5.36万 - 项目类别:
In vivo MRI Measures of Brain Metabolism in Traumatic Brain Injury
创伤性脑损伤中脑代谢的体内 MRI 测量
- 批准号:
10444479 - 财政年份:2022
- 资助金额:
$ 5.36万 - 项目类别:
Quantifying the Brain Metabolism Underlying Task-Based BOLD Imaging
量化基于任务的 BOLD 成像背后的大脑代谢
- 批准号:
10816746 - 财政年份:2022
- 资助金额:
$ 5.36万 - 项目类别:
Dynamics of cellular brain metabolism using mass spectrometry imaging
使用质谱成像研究细胞脑代谢动力学
- 批准号:
10418219 - 财政年份:2022
- 资助金额:
$ 5.36万 - 项目类别:
Brain metabolism during task-evoked and spontaneous activity in aging and Alzheimer's disease
衰老和阿尔茨海默病中任务诱发和自发活动期间的大脑代谢
- 批准号:
10585419 - 财政年份:2022
- 资助金额:
$ 5.36万 - 项目类别:
PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial
PhytoSERM 预防更年期相关脑代谢和认知能力下降的功效:双盲、随机、安慰剂对照 2 期临床试验
- 批准号:
10560591 - 财政年份:2022
- 资助金额:
$ 5.36万 - 项目类别: